

# Sowmya Viswanathan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4574811/publications.pdf>

Version: 2024-02-01

47  
papers

3,043  
citations

361296

20  
h-index

243529

44  
g-index

51  
all docs

51  
docs citations

51  
times ranked

4928  
citing authors

#	ARTICLE	IF	CITATIONS
1	Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells. <i>Stem Cells and Development</i> , 2012, 21, 2724-2752.	1.1	693
2	Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. <i>Cytotherapy</i> , 2019, 21, 1019-1024.	0.3	466
3	International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. <i>Cytotherapy</i> , 2016, 18, 151-159.	0.3	400
4	Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation. <i>Stem Cells Translational Medicine</i> , 2019, 8, 746-757.	1.6	141
5	A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. <i>Oncotarget</i> , 2017, 8, 89256-89268.	0.8	127
6	Soliciting Strategies for Developing Cell-Based Reference Materials to Advance Mesenchymal Stromal Cell Research and Clinical Translation. <i>Stem Cells and Development</i> , 2014, 23, 1157-1167.	1.1	112
7	Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency. <i>Cytotherapy</i> , 2019, 21, 289-306.	0.3	107
8	TLR3 or TLR4 Activation Enhances Mesenchymal Stromal Cell-Mediated Treg Induction via Notch Signaling. <i>Stem Cells</i> , 2017, 35, 265-275.	1.4	106
9	Ligand/Receptor Signaling Threshold (LIST) Model Accounts for gp130-Mediated Embryonic Stem Cell Self-Renewal Responses to LIF and HIL-6. <i>Stem Cells</i> , 2002, 20, 119-138.	1.4	85
10	Synovial fluid monocyte/macrophage subsets and their correlation to patient-reported outcomes in osteoarthritic patients: a cohort study. <i>Arthritis Research and Therapy</i> , 2019, 21, 26.	1.6	63
11	Current Concepts. <i>Sports Health</i> , 2015, 7, 38-44.	1.3	61
12	Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. <i>Haematologica</i> , 2012, 97, 1020-1028.	1.7	53
13	Towards predictive models of stem cell fate. <i>Cytotechnology</i> , 2003, 41, 75-92.	0.7	48
14	Supplementation-dependent differences in the rates of embryonic stem cell self-renewal, differentiation, and apoptosis. <i>Biotechnology and Bioengineering</i> , 2003, 84, 505-517.	1.7	45
15	Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. <i>Cytotherapy</i> , 2021, 23, 368-372.	0.3	45
16	<sup>19</sup> F-perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in vivo using clinical MRI parameters in a therapeutic cell setting. <i>Scientific Reports</i> , 2018, 8, 590.	1.6	42
17	Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. <i>Regenerative Medicine</i> , 2015, 10, 897-911.	0.8	41
18	Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential. <i>Cytotherapy</i> , 2020, 22, 602-605.	0.3	35

#	ARTICLE	IF	CITATIONS
19	Anti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseases. <i>Seminars in Cell and Developmental Biology</i> , 2020, 101, 87-103.	2.3	31
20	A Systematic Study of the Effect of Different Molecular Weights of Hyaluronic Acid on Mesenchymal Stromal Cell-Mediated Immunomodulation. <i>PLoS ONE</i> , 2016, 11, e0147868.	1.1	30
21	Recent progress on developing exogenous monocyte/macrophage-based therapies for inflammatory and degenerative diseases. <i>Cytherapy</i> , 2019, 21, 393-415.	0.3	23
22	A Simplified Method for the Aspiration of Bone Marrow from Patients Undergoing Hip and Knee Joint Replacement for Isolating Mesenchymal Stem Cells and <i>In Vitro</i> Chondrogenesis. <i>Bone Marrow Research</i> , 2016, 2016, 1-18.	1.7	21
23	Overcoming Challenges to Initiating Cell Therapy Clinical Trials in Rapidly Developing Countries: India as a Model. <i>Stem Cells Translational Medicine</i> , 2013, 2, 607-613.	1.6	20
24	Stage-specific differences in secretory profile of mesenchymal stromal cells (MSCs) subjected to early- vs late-stage OA synovial fluid. <i>Osteoarthritis and Cartilage</i> , 2017, 25, 737-741.	0.6	20
25	Mesenchymal stromal cells improve cardiac function and left ventricular remodeling in a heart transplantation model. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1481-1488.	0.3	19
26	Iron nanoparticle-labeled murine mesenchymal stromal cells in an osteoarthritic model persists and suggests anti-inflammatory mechanism of action. <i>PLoS ONE</i> , 2019, 14, e0214107.	1.1	19
27	Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon. <i>Cytherapy</i> , 2019, 21, 686-698.	0.3	17
28	Clonal evolution of stem and differentiated cells can be predicted by integrating cell-intrinsic and -extrinsic parameters. <i>Biotechnology and Applied Biochemistry</i> , 2005, 42, 119.	1.4	16
29	OCT4 expression mediates partial cardiomyocyte reprogramming of mesenchymal stromal cells. <i>PLoS ONE</i> , 2017, 12, e0189131.	1.1	16
30	Advances in organ-on-a-chip systems for modelling joint tissue and osteoarthritic diseases. <i>Osteoarthritis and Cartilage</i> , 2022, 30, 1050-1061.	0.6	16
31	Donor Mesenchymal Stromal Cells (MSCs) Undergo Variable Cardiac Reprogramming in Vivo and Predominantly Co-Express Cardiac and Stromal Determinants after Experimental Acute Myocardial Infarction. <i>Stem Cell Reviews and Reports</i> , 2014, 10, 304-315.	5.6	15
32	Consensus International Council for Commonality in Blood Banking Automation – International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. <i>Cytherapy</i> , 2021, 23, 1060-1063.	0.3	15
33	Current practices and reform proposals for the regulation of advanced medicinal products in Canada. <i>Regenerative Medicine</i> , 2015, 10, 647-663.	0.8	14
34	Hybrid Core-Shell Polymer Scaffold for Bone Tissue Regeneration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4533.	1.8	9
35	Strategy for an abbreviated in-house qualification of a commercially available Rapid Microbiology Method (RMM) for canadian regulatory approval. <i>Cytherapy</i> , 2017, 19, 1529-1536.	0.3	8
36	Proteinase-Mediated Macrophage Signaling in Psoriatic Arthritis. <i>Frontiers in Immunology</i> , 2020, 11, 629726.	2.2	8

#	ARTICLE	IF	CITATIONS
37	A tool for evaluating novel osteoarthritis therapies using multivariate analyses of human cartilage-synovium explant co-culture. <i>Osteoarthritis and Cartilage</i> , 2022, 30, 147-159.	0.6	7
38	Review of Patents and Commercial Opportunities Involving Mesenchymal Stromal Cells (MSCs) Therapies in Osteoarthritis. <i>Recent Patents on Regenerative Medicine</i> , 2014, 4, 1-15.	0.4	7
39	Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada. <i>Frontiers in Medicine</i> , 2019, 6, 58.	1.2	6
40	Overcoming the challenges of conducting translational research in cell therapy. <i>Frontiers of Medicine</i> , 2011, 5, 333-335.	1.5	3
41	Development and characterization of a new inbred transgenic rat strain expressing DsRed monomeric fluorescent protein. <i>Transgenic Research</i> , 2014, 23, 779-793.	1.3	3
42	In-house abbreviated qualification of a real-time polymerase chain reaction method and strategies to amplify mycoplasma detection in human mesenchymal stromal cells. <i>Cytotherapy</i> , 2021, 23, 1036-1044.	0.3	1
43	Bench-to-Bedside Development of MSC Therapies: A Multidisciplinary Approach. , 2013, , 279-315.		0
44	Regenerative Medicine Approaches for Treatment of Osteoarthritis. , 2015, , 235-255.		0
45	Undertaking Regenerative Medicine Studies with Blood Stem Cells. , 2012, , 1-7.		0
46	Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells. <i>Recent Patents on Regenerative Medicine</i> , 2012, 1, 228-248.	0.4	0
47	How the COVID-19 pandemic has affected rheumatology research. <i>Nature Reviews Rheumatology</i> , 2022, 18, 128-132.	3.5	0